Last reviewed 2026-04-20 · How we verify

Hylands Naturals Earache Drops (BELLADONNA)

Hylands Naturals Earache Drops, containing belladonna, are currently marketed for the treatment of swimmer's ear pain or itching. The product leverages its unique mechanism of action, which is believed to reduce inflammation and pain, as a key competitive advantage. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition.

At a glance

Approved indications

• Swimmer's ear pain or itching
• Clogged ears
• Ear pain or itching from other earaches

Common side effects

No common side effects on file.

Key clinical trials

• Premedication for Less Invasive Surfactant Administration Study (PRELISA) (PHASE4)
• The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial (NA)
• E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1,PHASE2)
• The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
• PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention (PHASE1,PHASE2)
• A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control (PHASE3)
• Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine (NA)
• Combination Effect of Optical Defocus and Low Dose Atropine in Myopia Control (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Hylands Naturals Earache Drops CI brief — competitive landscape report
• Hylands Naturals Earache Drops updates RSS · CI watch RSS
• Hyland's Inc. portfolio CI